Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Investopedia6d
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
The average weight loss among those taking the new drug was 15.7% after 68 weeks, compared to 3.1% for those taking a placebo. Shares sank to their lowest point in over a year after the release of ...
Novo Nordisk (NVO) Sinks after Weight-Loss Drug Trial Misses Expectations
Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...
Daily Mail7d
Fat jab warning for midlife women: As experts sound alarm over sudden weight loss, dieticians reveal the foods you SHOULD be eating, and the ones you must always avoid
Recent figures suggest that more than half a million people are taking either Mounjaro or Wegovy (the version ... advice often given to women over 50 using weight-loss jabs. We need to move ...
Concerns over Ozempic misuse and eating disorder risks prompt calls for increased screening
Health experts are concerned Ozempic and other GLP-1 agonist drugs may be inappropriately prescribed to people experiencing ...
I'm an obesity guru and NHS GP — you MUST read this before trying 'miracle fat jabs'
Fortunes are being blown on injectable hopes of a slimmer future but a simpler and cheaper alternative could actually be in ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...